Physician profile
Robert L Seward
NPI 1063402600
$14,435.15
in general payments reported to CMS, 2019-2025
38 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $1,263 · 2021: $2,120 · 2022: $2,225 · 2023: $2,420 · 2024: $2,735 · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,560.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,416.07 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,286.21 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,276.71 | 2019-2025 | Spravato, Invega, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $1,081.68 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $919.17 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $873.61 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $859.06 | 2022-2025 | Caplyta |
| Corium, LLC | $787.88 | 2022-2025 | Azstarys, Adlarity |
| Sunovion Pharmaceuticals INC. | $685.96 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $682.25 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $662.05 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $532.27 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $524.30 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $381.00 | 2022-2025 | Auvelity, Sunosi |
| Ironshore Pharmaceuticals INC. | $356.74 | 2019-2024 | Jornay Pm |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $329.64 | 2019-2025 | Dyanavel Xr |
| Almatica Pharma LLC | $269.51 | 2022-2025 | Loreev Xr, Gralise |
| E.R. Squibb & Sons, L.L.C. | $228.09 | 2024-2025 | Cobenfy |
| Allergan, INC. | $177.64 | 2019-2020 | |
| Eisai INC. | $163.87 | 2020-2022 | |
| Noven Therapeutics, LLC | $124.06 | 2021-2024 | Secuado, Xelstrym |
| Neos Therapeutics, LP | $120.02 | 2020-2025 | Adzenys Xr-Odt |
| Merck Sharp & Dohme LLC | $89.27 | 2019-2023 | Belsomra |
| Collegium Pharmaceutical, INC. | $89.20 | 2025 | Jornay Pm |
| Neuronetics, INC. | $83.46 | 2020-2024 | Neurostar Tms Therapy System |
| Vertical Pharmaceuticals, LLC | $63.90 | 2019-2020 | |
| Shire North American Group INC | $60.88 | 2019 | |
| Bausch Health US, LLC | $53.59 | 2022 | |
| Adlon Therapeutics L.P. | $41.01 | 2020-2021 | |
| Tms Neurohealth Centers INC. | $36.65 | 2025 | Tms Neurohealth Centers INC. |
| Alfasigma USA, INC. | $35.30 | 2020 | |
| Jazz Pharmaceuticals INC. | $32.96 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $26.68 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $26.44 | 2025 | Lumryz |
| Amgen INC. | $17.29 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.06 | 2022 | |
| Pfizer INC. | $13.35 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Seward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.